NASDAQ
26.12.25 | 22:00
1,330 US-Dollar
-2,21 % -0,030
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.12. | ALXO Presents Phase 2 Data Of Evorpacept In Frontline Indolent Non-Hodgkin Lymphoma At The ASH | 1 | RTTNews | ||
| 07.12. | ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting | 148 | GlobeNewswire (Europe) | - Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an... ► Artikel lesen | |
| 13.11. | Jefferies initiates coverage on ALX Oncology stock with Buy rating | 4 | Investing.com | ||
| 07.11. | ALX Oncology anticipates $2B-$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies | 6 | Seeking Alpha | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.11. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Earnings Call Transkript: ALX Oncology zeigt vielversprechende Fortschritte bei Medikamentenentwicklung in Q3 2025 | 2 | Investing.com Deutsch | ||
| 07.11. | ALX Oncology GAAP EPS of -$0.41 misses by $0.04 | 3 | Seeking Alpha | ||
| 07.11. | ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 195 | GlobeNewswire (Europe) | ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast... ► Artikel lesen | |
| 07.11. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 06.11. | Examining the Future: ALX Oncology Holdings' Earnings Outlook | 2 | Benzinga.com | ||
| 23.10. | Alx Oncology stock jumps after presenting preclinical ADC data at conference | 3 | Investing.com | ||
| 23.10. | Präklinische ADC-Daten beflügeln Aktie von Alx Oncology | 1 | Investing.com Deutsch | ||
| 23.10. | ALX Oncology stellt präklinische Daten für neuartigen EGFR-Krebswirkstoff vor | 7 | Investing.com Deutsch | ||
| 23.10. | ALX Oncology presents preclinical data for novel EGFR cancer drug | 1 | Investing.com | ||
| 03.10. | ALX Oncology to present CD47 biomarker data for evorpacept at SITC | 1 | Investing.com | ||
| 03.10. | ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 12.09. | ALX Oncology appoints board member Klencke as interim CMO | 2 | Investing.com | ||
| 12.09. | ALX Oncology CMO Alan Sandler Resigns; Appoints Board Member Barbara Klencke As Interim CMO | 1 | RTTNews | ||
| 12.09. | ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | 281 | GlobeNewswire (Europe) | Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from... ► Artikel lesen | |
| 12.09. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,388 | +3,10 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| MODERNA | 27,580 | 0,00 % | Forget Moderna Stock, This is a Much Better Buy | ||
| NOVAVAX | 5,766 | 0,00 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,000 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,880 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,816 | 0,00 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,404 | 0,00 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| EDITAS MEDICINE | 1,974 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,66 | 0,00 % | Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, Sanofi Open Wallets | SOUTH SAN FRANCISCO (dpa-AFX) - In a holiday-shortened week, the biotech sector saw a wave of FDA approvals, strategic acquisitions, and key clinical trial readouts - alongside several setbacks... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,780 | 0,00 % | Sarepta-Aktie: Das sind positive Entwicklungen! | Die Aktie von Sarepta Therapeutics hat in den vergangenen Wochen deutlich an Aufmerksamkeit gewonnen, nachdem regulatorische und strategische Entwicklungen neue Perspektiven für das Unternehmen eröffnet... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,520 | 0,00 % | Cathie Wood's ARK buys Weride, Pacific Biosciences stocks, sells Ibotta | ||
| EXELIXIS | 38,820 | 0,00 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 58,22 | 0,00 % | Hedge Fund and Insider Trading News: Steve Cohen, Ray Dalio, Warren Buffett, Alan Howard, Scott Bessent, Saba Capital Management, Halozyme Therapeutics Inc (HALO), Epsilon Energy Ltd (EPSN), and More | ||
| NEUROCRINE BIOSCIENCES | 124,05 | 0,00 % | Neurocrine: Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced that its Phase 3 KINECT-DCP study evaluating valbenazine in pediatric and adult participants with dyskinetic cerebral palsy... ► Artikel lesen | |
| VAXART | 0,282 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
ALX ONCOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,030 (-2,21 %) liegt der Kurs bei 1,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.